Emergent BioSolutions Inc. (0IGA.L)
| Chiusura precedente | 10,18 |
| Aperto | 10,09 |
| Denaro | 0,00 x N/D |
| Lettera | 0,00 x N/D |
| Min-Max giorno | 9,88 - 10,40 |
| Intervallo di 52 settimane | 9,88 - 10,40 |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | 459,025M |
| Beta (5 anni mensile) | 0,91 |
| Rapporto PE (ttm) | 1,46 |
| EPS (ttm) | 7,12 |
| Prossima data utili | 26 apr 2023 - 01 mag 2023 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
U.S. FDA Approves Over-the-Counter Designation for Emergent BioSolutions’ NARCAN® Nasal Spray, a Historic Milestone for the Opioid Overdose Emergency Treatment
NARCAN® Naloxone HCl Nasal Spray 4 mg is currently the first and only prescription strength naloxone nasal spray to receive over-the-counter status in the U.S., which is a critical step toward broadening accessExpected over-the-counter availability is anticipated by late summer of this year GAITHERSBURG, Md., March 29, 2023 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has approved NARCAN® Naloxone HCl Nasal Spray 4 m
- GlobeNewswire
Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022
Reports Q4 2022 total revenues of $331M resulting in FY 2022 total revenues of $1,121M, in line with prior guidanceReports Q4 2022 net loss of $88M and FY 2022 net loss of $224MReports Q4 2022 adjusted EBITDA of $34M and FY 2022 adjusted EBITDA of $26M, in line with prior guidanceReports Q4 2022 adjusted gross margin of 48% and FY 2022 adjusted gross margin of 41%For FY 2023, expects continued stability of revenues and further improvements in operations and normalizing of cost structure leading
- GlobeNewswire
Emergent BioSolutions Reports FDA Advisory Committees’ Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter Use
If approved by the FDA, NARCAN Nasal Spray will be the first 4 mg naloxone nasal spray switched from prescription status to over-the-counter use GAITHERSBURG, Md., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE:EBS) announced the U.S. Food and Drug Administration (FDA) Nonprescription Drugs Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee have unanimously voted in favor (a total of 19 votes) that the benefit-risk profile of NARCAN® (
